Language selection

Search

Details for: AIMOVIG

Company: NOVARTIS PHARMACEUTICALS CANADA INC

DIN DIN name Active Ingredient(s) Strength Dosage Form Route of Administration
02479613AIMOVIGERENUMAB70 MG / MLSOLUTIONSUBCUTANEOUS
02487306AIMOVIGERENUMAB140 MG / MLSOLUTIONSUBCUTANEOUS
Search Reported Side Effects Report a Side Effect

Summary Reports

Regulatory Decision Summary
Summary Safety Review - Aimovig (erenumab) - Assessing the Potential Risks of Non-Fatal Stroke, Non-Fatal Heart Attack and Cardiovascular Death

Consumer Information

The Consumer Information is not yet available in the Drug and Health Product Register. Try searching on the active ingredient(s) to find other similar products.

Date modified: